Literature DB >> 26937020

Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.

L R Gerak1, C P France2.   

Abstract

Opioid receptor agonists are effective for treating pain; however, tolerance and dependence can develop with repeated use. Combining opioids with cannabinoids can enhance their analgesic potency, although it is less clear whether combined treatment alters opioid tolerance and dependence. In this study, four monkeys received 3.2 mg/kg morphine alone or in combination with 1 mg/kg Δ(9)-tetrahydrocannabinol (THC) twice daily; the antinociceptive effects (warm water tail withdrawal) of morphine, the cannabinoid receptor agonists WIN 55,212 [(R)-(1)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate] and CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol), and the κ opioid receptor agonist U-50,488 (trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzenacetamide methanesulfonate) were examined before, during, and after treatment. To determine whether concurrent THC treatment altered morphine dependence, behavioral signs indicative of withdrawal were monitored when treatment was discontinued. Before treatment, each drug increased tail withdrawal latency to 20 seconds (maximum possible effect). During treatment, latencies did not reach 20 seconds for morphine or the cannabinoids up to doses 3- to 10-fold larger than those that were fully effective before treatment. Rightward and downward shifts in antinociceptive dose-effect curves were greater for monkeys receiving the morphine/THC combination than monkeys receiving morphine alone. When treatment was discontinued, heart rate and directly observable withdrawal signs increased, although they were generally similar in monkeys that received morphine alone or with THC. These results demonstrated that antinociceptive tolerance was greater during treatment with the combination, and although treatment conditions were sufficient to result in the development of dependence on morphine, withdrawal was not markedly altered by concurrent treatment with THC. Thus, THC can enhance some (antinociception, tolerance) but not all (dependence) effects of morphine.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26937020      PMCID: PMC4851324          DOI: 10.1124/jpet.115.231381

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  43 in total

1.  Thienorphine: receptor binding and behavioral effects in rhesus monkeys.

Authors:  Jun-Xu Li; Ginger L Becker; John R Traynor; Ze-Hui Gong; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-01-12       Impact factor: 4.030

2.  Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.

Authors:  David R Maguire; Wenjuan Yang; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2013-03-27       Impact factor: 4.030

Review 3.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

4.  Cannabinoid-opioid interaction in chronic pain.

Authors:  D I Abrams; P Couey; S B Shade; M E Kelly; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

5.  The use of clonidine in detoxification from opiates.

Authors:  H D Kleber; M S Gold; C E Riordan
Journal:  Bull Narc       Date:  1980

6.  The synergistic analgesic interactions between hydrocodone and ibuprofen.

Authors:  Yuri A Kolesnikov; Roger S Wilson; Gavril W Pasternak
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

7.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

8.  Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.

Authors:  S P Welch; D L Stevens
Journal:  J Pharmacol Exp Ther       Date:  1992-07       Impact factor: 4.030

Review 9.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 10.  Adverse effects of medical cannabinoids: a systematic review.

Authors:  Tongtong Wang; Jean-Paul Collet; Stan Shapiro; Mark A Ware
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

View more
  10 in total

1.  Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures.

Authors:  David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2020-05-12       Impact factor: 4.492

2.  Effects of the synthetic cannabinoid receptor agonist JWH-018 on abuse-related effects of opioids in rhesus monkeys.

Authors:  Lisa R Gerak; Peter F Weed; David R Maguire; Charles P France
Journal:  Drug Alcohol Depend       Date:  2019-06-29       Impact factor: 4.492

3.  OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Authors:  David R Maguire; Lisa R Gerak; Gerta Cami-Kobeci; Stephen M Husbands; Charles P France; Barbara Belli; Peter Flynn
Journal:  J Pharmacol Exp Ther       Date:  2019-11-20       Impact factor: 4.030

4.  Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.

Authors:  Peter F Weed; Lisa R Gerak; Charles P France
Journal:  Eur J Pharmacol       Date:  2018-05-26       Impact factor: 4.432

5.  Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.

Authors:  Vanessa Minervini; Sujata Dahal; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2016-11-30       Impact factor: 4.030

6.  OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.

Authors:  Lisa R Gerak; David R Maguire; Gerta Cami-Kobeci; Keith M Olson; John R Traynor; Stephen M Husbands; Charles P France; Lisette Acevedo; Barbara Belli; Peter Flynn
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

7.  Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.

Authors:  Richard A Slivicki; Shahin A Saberi; Vishakh Iyer; V Kiran Vemuri; Alexandros Makriyannis; Andrea G Hohmann
Journal:  J Pharmacol Exp Ther       Date:  2018-10-01       Impact factor: 4.030

Review 8.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

9.  Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.

Authors:  William R Arnold; Lauren N Carnevale; Zili Xie; Javier L Baylon; Emad Tajkhorshid; Hongzhen Hu; Aditi Das
Journal:  Nat Commun       Date:  2021-02-10       Impact factor: 17.694

Review 10.  Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature.

Authors:  Kiri L Wills; Linda A Parker
Journal:  Front Pharmacol       Date:  2016-06-28       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.